clinical trial · NCT05063565
TheraSphere With Durvalumab and Tremelimumab for HCC
Hepatocellular CarcinomaTheraSphere Y-90 glass microsphere therapyDurvalumab (Imfinzi) immunotherapyTremelimumab immunotherapy
brief summary
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
started
Nov 3, 2023
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Jul 31, 2026
detailed description
A global open-label, prospective, multi-center Phase II trial designed to assess the safety and efficacy of TheraSphere administered before initiation of Durvalumab with Tremelimumab in HCC patients who are not a candidate for resection, thermal ablation or liver transplant at the time of study entry.
official title
An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol